Post by dgriffin on Sept 15, 2009 19:48:18 GMT -5
Healthcare: Where Are We?
Reuters
WHAT CHANGES IS CONGRESS CONSIDERING?
* All individuals would be required to obtain insurance under all of the options being considered in the House of Representatives and the Senate.
* All the bills are expected to bar insurance companies from refusing to cover people or charging them more because of health history or gender.
* The bills are expected to call for sweeping insurance market reforms including limits on insurance premiums.
* The House bill would set up a new government-run insurance program to compete with private insurance companies. The Senate Finance Committee, chiefly to address Republican concerns, is instead looking at creating nonprofit medical cooperatives to compete with insurers.
* The House and Senate Finance Committee bills would both create state insurance exchanges to act as clearinghouses for individuals and small businesses to buy insurance.
* The Senate health committee bill includes a sliding scale of subsidies for the purchase of insurance for people with incomes up to 500 percent of the poverty level. The Senate Finance Committee bill would scale that back to 300 percent of the poverty level, about $66,150 for a family of four.
* The House Ways and Means Committee bill includes a graduated surtax on individuals making more than $350,000, $500,000 and $1 million.
WHAT IS INDUSTRY'S INVOLVEMENT?
* Hospitals opposed the Obama administration's original proposal for $220 billion in payment cuts, but have agreed to $155 billion in cuts over 10 years, in part from reduced Medicare and Medicaid payments.
* Insurers oppose creating a new government-run insurance program. They are discussing payment cuts for Medicare Advantage health plans for the elderly and disabled offered by some companies to compete against private insurers.
* Drug companies agreed to $80 billion in prescription drug discounts over the next 10 years, in part by reducing the cost of medicines for elderly Medicare patients. They oppose requiring lower prescription drug prices for poor, elderly people who qualify for both Medicare and Medicaid programs.
Brand-name drug makers want 12 to 14 years of exclusivity for new biotechnology medicines before cheaper, generic versions are approved by the Food and Drug Administration. The Obama administration has endorsed seven years of protection.
HERE for complete article:
www.reuters.com/article/GCA-HealthcareReform/idUKTRE56C61720090713
THERE for Reuters in-depth look at the issues facing Americans as the Obama administration and the Congress wrestle with healthcare policy.
www.reuters.com/news/globalcoverage/healthcarereform